1 / 13

Drug – Resistant Tuberculosis A Worldwide Epidemic Poses a New Challenge

Drug – Resistant Tuberculosis A Worldwide Epidemic Poses a New Challenge. Robert Loddenkemper , Barbara Hauer Deutsches Zentralkomitee zur Bekämpfung der Tuberkulose, Stralauer Platz 34, Berlin , Germany Dtsch Arztebl Int 2010; 107(1–2): 10–9 . Objective.

carney
Download Presentation

Drug – Resistant Tuberculosis A Worldwide Epidemic Poses a New Challenge

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Drug – Resistant TuberculosisA Worldwide Epidemic Poses a New Challenge Robert Loddenkemper, Barbara Hauer Deutsches Zentralkomitee zur Bekämpfung der Tuberkulose, StralauerPlatz34, Berlin, Germany Dtsch Arztebl Int 2010; 107(1–2): 10–9

  2. Objective • to obtain insight into the problem of resistance development in tuberculosis; • to master the fundamentals of the diagnosis and treatment of drug-resistant tuberculosis; • to be able to assess epidemiological developments in this area.

  3. Epidemiology • 2007: 9.27M new cases of Tb and 1.78M deaths • WHO report of increase to 5% of ~9 million TB patients are infected with drug – resistant TB in 2008 • MDR-TB or XDR-TB • resistant to at least one of the fluoroquinolonesand to one of the threeeinjectable second – line anti – TB drugs (amikacin, kanamycin and capreomycin) • WHO reported 2.9% MDR-TB cases • 2006: 20% of 17,000 isolates is MDR; 2% extensive resistance 2%; extremely extensive resistance is present

  4. WHO estimated incidence of tuberculosis (all types) per 100 000 population per year in the world population for the year 2007

  5. 45 countries with confirmed cases of XDR tuberculosis by February 2008; the number rose to 55 countries by the end of 2008.

  6. Estimated percentage of multidrug-resistant (MDR) tuberculosis in newly diagnosed andnotpreviously treated tuberculosis patients worldwide, from 1994 to 2007.

  7. Risk factors for MDR-TB • Prior anti-TB treatment • Immigration from a region with a high prevalence of MDR-TB • Contact with MDR-TB patients • Imprisonment • Possibly, HIV infection

  8. Development of resistance to the five first-line anti-tuberculosis drugs used in Germany from 2002 to 2007

  9. Diagnosis of drug – resistant TB • Confirmed only with the aid of standardized, quality – controlled bacteriological sensitivity testing • Gold standard of resistance testing: culture • New technique: MODS or Microscopic Observation of Drug Susceptibility

  10. Treatment • Non – resistant TB: standard chemotherapy • Antibiotic resitance: treatment may last up to 2 years and is often poorly tolerated • requires a high degree of patient cooperation • extensive patient education and counseling are needed • Supportive measures • Surgery indicated only for selected patients

  11. Strategy for Drug - resistance • WHO Goal: lower new infections and death rate from TB to half by 2015 • 2050: eradication of the disease • Prerequisite for prevention: adherence to the stated principles of treatment; DOTS • Strategy: DOTS • Extended: DOTS-plus • WHO Green Light Committee • Global Stop TB Partnership

More Related